{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:56:50Z","timestamp":1790243810726,"version":"4.1.0"},"reference-count":42,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2012,1,23]],"date-time":"2012-01-23T00:00:00Z","timestamp":1327276800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Ophthalmologica"],"published-print":{"date-parts":[[2012,11]]},"abstract":"<jats:title>Abstract.<\/jats:title><jats:p>Topically applied carbonic anhydrase inhibitors (CAIs) in eye drop solutions are commonly used to treat glaucoma. However, local eye irritation and multiple daily administrations may hamper their clinical usefulness. Aqueous eye drop formulations that improve their topical bioavailability and reduce their eye irritation can improve their clinical efficacy. Earlier studies showed that dorzolamide and closely related CAIs are more effectively delivered into the eye from acidic eye drop solutions than from comparable neutral solutions. Consequently, dorzolamide was marketed as an aqueous pH 5.6 eye drop solution (Trusopt<jats:sup>\u00ae<\/jats:sup>, Merck). Later, it was shown that increasing the pH of the eye drops from pH 5.6 to physiologic pH significantly reduced their local irritation. Earlier attempts to use cyclodextrins (CDs) as ocular penetration enhancers in dorzolamide eye drop solutions failed since; although the CDs were able to enhance the aqueous solubility of dorzolamide, increasing the pH from 5.6 to physiologic pH reduced the ability of the drug to permeate into the eye. Later, it was discovered that formulating the drug as aqueous dorzolamide\/\u03b3CD eye drop microparticle suspension resulted in significant bioavailability enhancement. The solid dorzolamide\/\u03b3CD microparticles are mucoadhesive and release dorzolamide into the aqueous tear fluid for extended time period. Consequently, sustained high dorzolamide concentrations in aqueous humour and various eye tissues were observed after single administration of the aqueous dorzolamide\/\u03b3CD eye drop microsuspension. The microsuspension has a potential of being developed into a once\u2010a\u2010day eye drop product. This article reviews the physicochemical properties of dorzolamide, its permeation characteristics and topical bioavailability.<\/jats:p>","DOI":"10.1111\/j.1755-3768.2011.02299.x","type":"journal-article","created":{"date-parts":[[2012,1,23]],"date-time":"2012-01-23T12:00:23Z","timestamp":1327320023000},"page":"603-608","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Topical drug delivery to the eye: dorzolamide"],"prefix":"10.1111","volume":"90","author":[{"given":"Thorsteinn","family":"Loftsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phatsawee","family":"Jansook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar","family":"Stef\u00e1nsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,23]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.20294"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.21803"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-009-9268-4"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cocis.2005.11.001"},{"key":"e_1_2_6_6_1","first-page":"2581","article-title":"pH and drug ionization affects ocular pressure lowering of topical carbonic anhydrase inhibitors","volume":"34","author":"Brechue WF","year":"1993","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2007.05.012"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600810322"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-4835(05)80041-7"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.22033"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-008-9694-0"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2009.398"},{"key":"e_1_2_6_13_1","first-page":"479","volume-title":"Minutes of the 5th International Symposium on Cyclodextrins","author":"Grove J","year":"1990"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2008.07.011"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.21861"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10847-010-9779-3"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2010.07.005"},{"key":"e_1_2_6_18_1","first-page":"1199","article-title":"Dexamethasone\u2010cyclodextrin\u2010polymer co\u2010complexes in aqueous eye drops","volume":"37","author":"Kristinsson JK","year":"1996","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0608611104"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1023088423667"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1021\/js950534b"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.2010.01030.x"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2006.10.044"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1773-2247(07)50001-8"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1994.tb03835.x"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.2165\/00137696-200402040-00006"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20992"},{"key":"e_1_2_6_28_1","first-page":"171","article-title":"Topical drug delivery to the posterior segment of the eye: anatomical and physiological considerations","volume":"63","author":"Loftsson T","year":"2008","journal-title":"Pharmazie"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/00061198-199502000-00012"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-4835(90)90007-H"},{"key":"e_1_2_6_31_1","volume-title":"TRUSOPT\u00ae (Dorzolamide Hydrochloride Ophthalmic Solution), Package Insert","author":"Merck & Co.","year":"2009"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(98)00054-4"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2009.11.035"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2004.05.008"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/00055735-199404000-00005"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/0378-5173(90)90179-8"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600670614"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1159\/000050856"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.21200"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2004.10.004"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/0163-7258(89)90049-1"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1010-6030(98)00359-1"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0939-6411(97)00064-7"}],"container-title":["Acta Ophthalmologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1755-3768.2011.02299.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1755-3768.2011.02299.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T14:07:08Z","timestamp":1697378828000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1755-3768.2011.02299.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,23]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["10.1111\/j.1755-3768.2011.02299.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1755-3768.2011.02299.x","archive":["Portico"],"relation":{},"ISSN":["1755-375X","1755-3768"],"issn-type":[{"value":"1755-375X","type":"print"},{"value":"1755-3768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,23]]},"assertion":[{"value":"2012-01-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}